10-K · March 25, 2026
Atossa is a clinical-stage biopharmaceutical company focused on developing oral (Z)-endoxifen across multiple Phase 2 programs in ER+ breast cancer and exploring rare disease indications (e.g., DMD, MAS). The company…
Earnings analysis · 10-Q
ATOS earnings analysis
Filed May 8, 2026 · Our reading of the company's report
The latest report
Atossa Therapeutics, Inc. reported significant operating losses in Q1 2026 with an EPS of -0.03, falling short of consensus expectations. Revenue remains non-existent, reflecting ongoing challenges in monetizing their…
Read full summary
Atossa Therapeutics, Inc. reported significant operating losses in Q1 2026 with an EPS of -0.03, falling short of consensus expectations. Revenue remains non-existent, reflecting ongoing challenges in monetizing their product development despite promising research efforts. Management expressed continued uncertainties about future capital and operational viability, indicating reliance on further funding to sustain activities going forward.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.03
What stood out
-
EPS Beat Expectations
Reported EPS was -0.03, exceeding estimates of -1.11 by 0.973.
-
No Revenue Generated
Total revenue for Q1 2026 stood at $0, consistent with the previous quarters.
-
Increased Operating Expenses
Operating expenses rose to $9.9 million in Q1 2026, up from $7.4 million in Q1 2025.
-
Cash Position Decline
Cash and cash equivalents decreased to $31.7 million as of March 31, 2026.
-
R&D Expense Increase
R&D expenses rose 15%, from $4.15 million in Q1 2025 to $4.78 million in Q1 2026.
-
Management Signals Ongoing Losses
Management warns about future capital needs and expresses doubt about the ability to continue operations without additional funding.
What to watch
-
Significant Operating Losses
Net loss for Q1 2026 was $9.6 million, highlighting ongoing financial challenges.
-
Lack of Revenue Sources
The company has not established a source of revenue, raising liquidity concerns.
-
Capital Raising Risks
Management indicates the need for substantial capital to sustain operations without assurance of successful fundraising.
Management's outlook
Management did not provide specific numeric guidance in the filing.
Earlier filings 4
10-K · March 25, 2025
Atossa is a clinical-stage biopharmaceutical company focused on developing oral (Z)-endoxifen for breast cancer prevention and treatment. The 10-K highlights multiple Phase 2 data readouts showing biomarker and imaging…
10-Q · November 13, 2023
Atossa reported a Q3 2023 net loss of $6,229 (loss per share $(0.05)), an improvement from Q3 2022 net loss of $8,011 (loss per share $(0.06)). Cash declined to $94,031 (from $110,890 at Dec 31, 2022) but management…
10-Q · August 14, 2023
Atossa reported a Q2 net loss of $9,830,000 (loss per share $0.08) versus a prior-year Q2 net loss of $6,672,000 (loss per share $0.05), driven by higher operating expenses and a $2,990,000 impairment on an equity…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.